India Pharma Outlook Team | Wednesday, 12 November 2025
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., has announced new findings from the ongoing real-world IMPACT-TD Registry, which underscore the beneficial effects of AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets for individuals suffering from tardive dyskinesia (TD).
The pharmaceutical company's findings, shared at the 2025 Neuroscience Education Institute Fall Congress in Colorado Springs, Colorado, revealed that pharmaceutical treatment with AUSTEDO or AUSTEDO XR resulted in significant reductions in the severity of involuntary movements and marked enhancements in patient-reported quality of life.
Also Read: Roche's Fenebrutinib Marks Breakthrough in MS Trials
The interim analysis assessed 27 adults with TD after three months of treatment using the IMPACT-TD PRO, a 30-item patient-reported outcomes scale that evaluates the impact of TD across five essential life domains.
The participants represented a real-world patient demographic, with many also experiencing comorbid psychiatric disorders and health issues such as bipolar disorder (41 percent), anxiety disorder (37 percent), depression (26 percent), and schizophrenia (19 percent).
Patients indicated considerable improvements in various facets of daily living, including communication, eating, psychosocial functioning, and activities of daily living.
The overall motor score on the Abnormal Involuntary Movement Scale (AIMS) exhibited a mean decrease of 2.9 points, reflecting a significant reduction in the severity of involuntary movements, consistent with findings from pivotal clinical trials.
Notably, 85 percent of participants using AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their psychiatric conditions either remained stable or improved during the same timeframe.
